-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Equal-Weight on Myriad Genetics, Lowers Price Target to $3

Benzinga·08/03/2026 14:00:02
语音播报
Wells Fargo analyst Evan Stampler maintains Myriad Genetics (NASDAQ:MYGN) with a Equal-Weight and lowers the price target from $5.5 to $3.